Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 5/2010

01.10.2010

Visual Dysfunction Associated with Diabetic Retinopathy

verfasst von: Gregory R. Jackson, Alistair J. Barber

Erschienen in: Current Diabetes Reports | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Diabetic retinopathy is a leading cause of blindness and is commonly viewed as a vascular complication of diabetes mellitus. However, diabetes mellitus causes visual dysfunction before the onset of clinically visible microvascular changes associated with diabetic retinopathy. Thus, viewing diabetic retinopathy more generally as a neurovascular disease may lead to an improved understanding of the mechanisms responsible for vision loss. This article reviews the impact of diabetes mellitus on inner and outer retinal visual and electrophysiologic function and advocates for a multimodal approach to the study of diabetic retinopathy.
Literatur
1.
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group [no authors listed]. Ophthalmology 1991, 98(5 Suppl):766–785.
2.
Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008, 115:1447–1449, 1449.e1441–1449.e1410.
3.
Beck RW, Edwards AR, Aiello LP, et al.: Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009, 127:245–251.CrossRefPubMed
4.
Aiello LP, Edwards AR, Beck RW, et al.: Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010, 117:946–953.CrossRefPubMed
5.
Scott IU, Edwards AR, Beck RW, et al.: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007, 114:1860–1867.CrossRefPubMed
6.
•• Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al.: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117:1064–1077.e35. This article demonstrates ranibizumab in combination improves vision in patients with DME. It provides hope for treatments of DME that may preserve vision better than laser, which ablates the retina.CrossRefPubMed
7.
Nguyen QD, Shah SM, Heier JS, et al.: Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009, 116:2175–2181.e1.CrossRefPubMed
8.
Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group [no authors listed]. Ophthalmology 1981, 88:583–600.
9.
Bresnick GH: Diabetic retinopathy viewed as a neurosensory disorder. Arch Ophthalmol 1986, 104:989–990.PubMed
10.
•• Gardner T, Abcouwer S, Antonetti D, et al.: Pathogenesis of diabetic retinopathy. Arch Ophthalmol 2010, in press. Gardner et al. present the case that DR should be viewed as a neurodegenerative disease much as other complications of diabetes such as neuropathy are viewed. A comprehensive approach to the study of DR is proposed that integrates the best of basic and translational research.
11.
Wolter JR: Diabetic retinopathy. Am J Ophthalmol 1961, 51:1123–1141.PubMed
12.
Barber AJ, Antonetti DA, Kern TS, et al.: The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005, 46:2210–2218.CrossRefPubMed
13.
Barber AJ, Lieth E, Khin SA, et al.: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998, 102:783–791.CrossRefPubMed
14.
Gastinger MJ, Kunselman AR, Conboy EE, et al.: Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci 2008, 49:2635–2642.CrossRefPubMed
15.
Parravano M, Oddone F, Mineo D, et al.: The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. Br J Ophthalmol 2008, 92:1656–1660.CrossRefPubMed
16.
Parikh R, Naik M, Mathai A, et al.: Role of frequency doubling technology perimetry in screening of diabetic retinopathy. Indian J Ophthalmol 2006, 54:17–22.CrossRefPubMed
17.
Sieving PA, Nino C: Scotopic threshold response (STR) of the human electroretinogram. Invest Ophthalmol Vis Sci 1988, 29:1608–1614.PubMed
18.
Aylward GW, Billson FA: The scotopic threshold response in diabetic retinopathy--a preliminary report. Aust N Z J Ophthalmol 1989, 17:369–372.CrossRefPubMed
19.
Caputo S, Di Leo MA, Falsini B, et al.: Evidence for early impairment of macular function with pattern ERG in type I diabetic patients. Diabetes Care 1990, 13:412–418.CrossRefPubMed
20.
Bresnick GH, Palta M: Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol 1987, 105:929–933.PubMed
21.
Vadala M, Anastasi M, Lodato G, Cillino S: Electroretinographic oscillatory potentials in insulin-dependent diabetes patients: a long-term follow-up. Acta Ophthalmol Scand 2002 80:305–309.CrossRefPubMed
22.
Bresnick GH, Palta M: Predicting progression to severe proliferative diabetic retinopathy. Arch Ophthalmol 1987, 105:810–814.PubMed
23.
van Dijk HW, Kok PH, Garvin M, et al.: Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 2009, 50:3404–3409.CrossRefPubMed
24.
Van Dijk HW, Verbraak FD, Kok PH, et al.: Decreased retinal ganglion cell layer thickness in type 1 diabetic patients. Invest Ophthalmol Vis Sci 2010, 51:3660–3665.CrossRefPubMed
25.
Cabrera DeBuc D, Somfai GM: Early detection of retinal thickness changes in diabetes using optical coherence tomography. Med Sci Monit 2010, 16:MT15–MT21.PubMed
26.
Takahashi H, Goto T, Shoji T, et al.: Diabetes-associated retinal nerve fiber damage evaluated with scanning laser polarimetry. Am J Ophthalmol 2006, 142:88–94.CrossRefPubMed
27.
Henson DB, Williams DE: Normative and clinical data with a new type of dark adaptometer. Am J Optom Physiol Opt 1979, 56:267–271.PubMed
28.
Greenstein VC, Thomas SR, Blaustein H, et al.: Effects of early diabetic retinopathy on rod system sensitivity. Optom Vis Sci 1993, 70:18–23.CrossRefPubMed
29.
Holopigian K, Seiple W, Lorenzo M, Carr R: A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1992, 33:2773–2780.PubMed
30.
Abraham FA, Haimovitz J, Berezin M: The photopic and scotopic visual thresholds in diabetics without diabetic retinopathy. Metab Pediatr Syst Ophthalmol 1988, 11:76–77.PubMed
31.
Holopigian K, Greenstein VC, Seiple W, et al.: Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 1997, 38:2355–2365.PubMed
32.
Mantyjarvi M: Colour vision and dark adaptation in diabetic patients after photocoagulation. Acta Ophthalmol (Copenh) 1989, 67:113–118.CrossRef
33.
Henson DB, North RV: Dark adaptation in diabetes mellitus. Br J Ophthalmol 1979, 63:539–541.CrossRefPubMed
34.
Pender PM, Benson WE, Compton H, Cox GB: The effects of panretinal photocoagulation on dark adaptation in diabetics with proliferative retinopathy. Ophthalmology 1981, 88:635–638.PubMed
35.
Arden GB, Wolf JE, Tsang Y: Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis. Vision Res 1998, 38:1723–1729.CrossRefPubMed
36.
Harris A, Arend O, Danis RP, et al.: Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br J Ophthalmol 1996, 80:209–213.CrossRefPubMed
37.
Holfort SK, Klemp K, Kofoed PK, et al.: Scotopic electrophysiology of the retina during transient hyperglycemia in type 2 diabetes. Invest Ophthalmol Vis Sci 2010, 51:2790–2794.CrossRefPubMed
38.
Verrotti A, Lobefalo L, Altobelli E, et al.: Static perimetry and diabetic retinopathy: a long-term follow-up. Acta Diabetol 2001, 38:99–105.CrossRefPubMed
39.
Bengtsson B, Heijl A, Agardh E: Visual fields correlate better than visual acuity to severity of diabetic retinopathy. Diabetologia 2005, 48:2494–2500.CrossRefPubMed
40.
Greenstein VC, Hood DC, Ritch R, et al.: S (blue) cone pathway vulnerability in retinitis pigmentosa, diabetes and glaucoma. Invest Ophthalmol Vis Sci 1989, 30:1732–1737.PubMed
41.
Cho NC, Poulsen GL, Ver Hoeve JN, Nork TM: Selective loss of S-cones in diabetic retinopathy. Arch Ophthalmol 2000, 118:1393–1400.PubMed
42.
Agardh E, Stjernquist H, Heijl A, Bengtsson B: Visual acuity and perimetry as measures of visual function in diabetic macular oedema. Diabetologia 2006, 49:200–206.CrossRefPubMed
43.
Frost-Larsen K, Larsen HW: Macular recovery time recorded by nyctometry--a screening method for selection of patients who are at risk of developing proliferative diabetic retinopathy. Results of a 5-year follow-up. Acta Ophthalmol Suppl 1985, 173:39–47.CrossRefPubMed
44.
Frost-Larsen K, Lund-Anderson C, Starup K: Macular recovery during onset and development of diabetic retinopathy in childhood and adolescence. Acta Ophthalmol (Copenh) 1989, 67:401–404.CrossRef
Metadaten
Titel
Visual Dysfunction Associated with Diabetic Retinopathy
verfasst von
Gregory R. Jackson
Alistair J. Barber
Publikationsdatum
01.10.2010
Verlag
Current Science Inc.
Erschienen in
Current Diabetes Reports / Ausgabe 5/2010
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-010-0132-4

Weitere Artikel der Ausgabe 5/2010

Current Diabetes Reports 5/2010 Zur Ausgabe

ReviewPaper

Virus Infections and Type 1 Diabetes Risk

Clinical Trial Report

Loss and Preservation of β-Cell Function: Two Treatment Regimes Targeting T or B Lymphocytes

ReviewPaper

Virus Infections: Lessons from Pancreas Histology

ReviewPaper

Infant and Childhood Diet and Type 1 Diabetes Risk: Recent Advances and Prospects

ReviewPaper

Pediatric Islet Autotransplantation: Indication, Technique, and Outcome

Clinical Trial Report

The Cardinal Features of Recurrent Autoimmunity in Simultaneous Pancreas-Kidney Transplant Recipients

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise